drugset / Trial / NCT06723535
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278. This study plans to use a staged design based on RI severity.
Timeline
- Start
- 2024-12-07
- Primary completion
- 2025-09-16
- Completion
- 2025-09-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Admilparant | Small molecule | — | — |